The new crown Omicron variant is spreading around the world, and the US pharmaceutical company Pfizer is developing a mixed vaccine against Omicron. The Taiwanese high-end vaccine (6547-TW) is also developing second-generation vaccines for Omicron and Beta, and has entered animal testing. The preliminary test results are expected to be announced within one month.
The Omicron epidemic is heating up. The industry believes that the existing new crown vaccines do not have enough antibodies to fight against the mutant virus. In the future, second-generation vaccines will be needed to deal with Omicron and other mutant strains. Pfizer is developing a hybrid new crown vaccine that combines the original vaccine with the formulation of the Omicron variant, and is expected to apply for a license from U.S. regulators in March.
High-end has also followed international steps to develop a second-generation vaccine, and has initially completed the construction of the Omicron virus platform and tested it with another large variant strain Beta. It is expected that the animal test data results will be released within a month.
High-end supplements, because the role of vaccines is to prevent the incidence of severe cases, and although Omicron spreads quickly and has a large number of infections, the number of severe infections is low; on the other hand, Beta is a virus that causes more severe infections. Generation vaccines are mostly tested in beta.
As for the neutralizing antibody titer of the high-end existing new crown vaccine against Omicron, the high-end use of the first phase of the clinical extension trial, the subjects were administered with 2+1 vaccine sera to test, according to experimental data, the new crown vaccine Omicron neutralizing antibodies decreased by about 6.4-8.7 times, and the serum of most subjects still had neutralizing ability and provided some protection.
The high-end pointed out that according to the analysis of relevant literature, the titer of the existing mRNA vaccine to Omicron’s pseudovirus neutralizing antibody decreased by about 4-6 times, and the decline trend of the sub-unit vaccine was similar to that of the mRNA vaccine, but both were better than the adenovirus vector. vaccine.
The high-end believes that Omicron does have an impact on the protection of existing vaccines, but it is not completely immune, and the protection of the vaccine can be maintained by administering the third injection or mixing across vaccine platforms.